<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2863">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04591210</url>
  </required_header>
  <id_info>
    <org_study_id>CTO-3212</org_study_id>
    <nct_id>NCT04591210</nct_id>
  </id_info>
  <brief_title>The COVID-RASi Trial (COVID-19)</brief_title>
  <official_title>Evaluation of the Potential Benefit of Renin-angiotensin System Inhibitors (RASi, ACEi/ARB) in High-risk Patients With COVID-19. The COVID-RASi Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ottawa Heart Institute Research Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The COVID-RASi study is an international randomized clinical trial that will evaluate the&#xD;
      potential benefit of angiotensin modulators on clinical outcomes, in older COVID-19 patients&#xD;
      who are at high-risk for cardiovascular disease. The purpose of this study is to determine if&#xD;
      renin-angiotensin system inhibitors (RASi), with angiotensin-converting enzyme inhibitors&#xD;
      (ACEi) or angiotensin II receptor blockers (ARB), has a beneficial effect in high-risk older&#xD;
      patients with COVID-19 infections, by reducing ICU admission, ventilator requirement or&#xD;
      death. We would also like to determine if there are differences between ACEi and ARB&#xD;
      therapeutic treatments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 30, 2020</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>To minimize subjective bias, some research staff conducting follow-ups will remain blinded to randomized treatment allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>28 days</time_frame>
    <description>Within first 28 days post randomization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mechanical ventilation</measure>
    <time_frame>28 days</time_frame>
    <description>Within first 28 days post randomization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ICU admission</measure>
    <time_frame>28 days</time_frame>
    <description>Within first 28 days post randomization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>28 days</time_frame>
    <description>Within first 28 days post randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days alive and out of hospital</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and out of hospital</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause hospitalization</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients require intensive care</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients requiring ventilation</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients requiring dialysis</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1155</enrollment>
  <condition>COVID-19</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>No Treatment (Standard of Care)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will be treated as per standardized care pathway according to province/state and institutional guidelines. Physicians will be reminded not to start ACEi or ARB throughout admission or to outpatients until active study participation is complete at 28 days post symptoms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACEi treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The physician will initiate any ACE inhibitor and dose at their discretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARB treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The physician will initiate any ARB and dose at their discretion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angiotensin converting enzyme inhibitor</intervention_name>
    <description>The study recommends physicians to select an ACEi with proven benefit in cardiovascular diseases such as perindopril, ramipril or enalapril. Lab values will be obtained during baseline. The patient will be followed by the physician clinically, with recommended laboratory testing in one week, including renal function, potassium assessment, and dose adjustments as appropriate.</description>
    <arm_group_label>ACEi treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angiotensin II Receptor Blockers</intervention_name>
    <description>The study recommends physicians to select evidence-based ARBs such as candesartan or valsartan or losartan. Lab values will be obtained during baseline. The patient will be followed by the physician clinically, with recommended laboratory testing in one week, and dose adjustments as appropriate.</description>
    <arm_group_label>ARB treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with COVID-19 diagnosis with polymerase chain reaction (PCR) confirmation&#xD;
             within the last 3 days AND&#xD;
&#xD;
          -  65 years old or greater&#xD;
&#xD;
          -  AND At least one of the following: Hypertension (BP&gt;140/90 mmHg) or with history of&#xD;
             hypertension, diabetes, coronary artery disease, history of myocardial infarction&#xD;
             (NSTEMI or STEMI), history of ischemic stroke, heart failure (LVEF&gt;40%), or renal&#xD;
             dysfunction (30 ≤ estimated glomerular filtration rate (eGFR) &lt; 90 ml/min/1.73 m2).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to ARB or ACEi, including severe aortic stenosis and angioedema&#xD;
&#xD;
          -  Patients who are currently on active treatment with ARB/ACEi&#xD;
&#xD;
          -  Known bilateral renal artery stenosis&#xD;
&#xD;
          -  Systolic BP ≤90 mmHg&#xD;
&#xD;
          -  eGFR&lt;30 ml/min or K&gt;5.5 mmol/L on screening laboratory testing&#xD;
&#xD;
          -  Recent history of dizziness, vertigo, or orthostatic hypotension&#xD;
&#xD;
          -  LVEF ≤ 40%&#xD;
&#xD;
          -  Acute respiratory distress syndrome requiring invasive ventilation&#xD;
&#xD;
          -  Immunosuppression or immunocompromised conditions other than COVID-19.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ermina Moga</last_name>
    <phone>6136967000</phone>
    <phone_ext>10945</phone_ext>
    <email>EMoga@ottawaheart.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Ermina Moga</last_name>
      <phone>613-696-7000</phone>
      <phone_ext>10945</phone_ext>
      <email>EMoga@ottawaheart.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 15, 2020</last_update_submitted>
  <last_update_submitted_qc>October 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiovascular risk factors</keyword>
  <keyword>corona virus</keyword>
  <keyword>COVID-19</keyword>
  <keyword>severe acute respiratory syndrome coronavirus 2 (SARS-COV-2)</keyword>
  <keyword>elderly</keyword>
  <keyword>senior</keyword>
  <keyword>Angiotensin-converting enzyme inhibitors</keyword>
  <keyword>ACEi</keyword>
  <keyword>Renin-angiotensin system inhibitors</keyword>
  <keyword>RASi</keyword>
  <keyword>Angiotensin receptor blockers</keyword>
  <keyword>ARB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiotensin II</mesh_term>
    <mesh_term>Giapreza</mesh_term>
    <mesh_term>Enzyme Inhibitors</mesh_term>
    <mesh_term>Angiotensinogen</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

